Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCORD 2 COVID-19 adaptive platform study in hospitalized patients
2020-001736-95Phase 2Unknown
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Apr 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of bemcentinib, tozorakimab, zilucoplan and acalabrutinib in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Time to sustained clinical improvement. Status: unknown.
02
Drugs
bemcentinibtozorakimabzilucoplanacalabrutinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001736-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001736-95.